|
Volumn 23, Issue 5, 2010, Pages
|
Meeting report from the third global workshop on melanoma
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
B RAF KINASE;
BEVACIZUMAB;
CARBOPLATIN;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY;
DACARBAZINE;
GSK 2118436;
IPILIMUMAB;
MELPHALAN;
PACLITAXEL;
PEGINTERFERON;
PLACEBO;
PLX 4032;
R 05185426;
STEM CELL FACTOR;
UNCLASSIFIED DRUG;
ANTIANGIOGENIC THERAPY;
CANCER ADJUVANT THERAPY;
CLINICAL TRIAL;
CONFERENCE PAPER;
DEPRESSION;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
FATIGUE;
HUMAN;
LIVER PERFUSION;
LIVER TOXICITY;
MELANOMA;
PATIENT CARE;
ANGIOGENESIS INHIBITORS;
ANTIGENS, CD;
ANTINEOPLASTIC AGENTS;
CHEMOTHERAPY, ADJUVANT;
CLINICAL TRIALS AS TOPIC;
CONGRESSES AS TOPIC;
GERMANY;
HUMANS;
IMMUNOLOGIC FACTORS;
INTERFERON-ALPHA;
MELANOMA;
PROTO-ONCOGENE PROTEINS B-RAF;
PROTO-ONCOGENE PROTEINS C-KIT;
SKIN NEOPLASMS;
|
EID: 77956323144
PISSN: 17551471
EISSN: 1755148X
Source Type: Journal
DOI: 10.1111/j.1755-148X.2010.00738.x Document Type: Conference Paper |
Times cited : (6)
|
References (0)
|